ECHOIQ LIMITED (EIQ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EIQ

EIQ - ECHOIQ LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Software & Services
Debt/EBITDA: -0
Index: ALL-ORDS | ALL-TECH

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.225

03 Sep
2026

-0.060

OPEN

$1.30

-4.67%

HIGH

$1.32

4,478,839

LOW

$1.22

TARGET
$1.867 52.4% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ .
FNARENA'S MARKET CONSENSUS FORECASTS
EIQ: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 2.8 1.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 79.8 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-2.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.1 M
Book Value Per Share xxxxxxxxxxxxxxx1.8
Net Operating Cash Flow xxxxxxxxxxxxxxx-10.6 M
Net Profit Margin xxxxxxxxxxxxxxx-20,180.43 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-107.99 %
Return on Invested Capital xxxxxxxxxxxxxxx-107.99 %
Return on Assets xxxxxxxxxxxxxxx-99.69 %
Return on Equity xxxxxxxxxxxxxxx-107.99 %
Return on Total Capital xxxxxxxxxxxxxxx-115.44 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-10.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx9 M
Price To Book Value xxxxxxxxxxxxxxx90.34

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx57.61 %
Cost of Goods Sold xxxxxxxxxxxxxxx16 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx4 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

01/09/2026

3

Speculative Hold

$1.75

42.86%

Echo IQ reported a normalised FY26 operating loss of -$12.4m as the company remains in the early stages of commercialisation with negligible revenue, Bell Potter explains.

The broker highlights two key upcoming catalysts: potential US reimbursement for AI-based diagnostic software from January 2027 and a US FDA decision on the EchoSolv heart failure diagnostic in the 2H of 2026.

Following a $120m capital raising, the company is considered well-funded with a pro-forma cash balance of around $130m.

The broker retains its Hold (Speculative) rating and $1.75 target.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -2.20 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of minus -1.30 cents.

Ord Minnett

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Shaw and Partners

01/09/2026

3

Downgrade to Hold from Buy

$1.50

22.45%

Shaw and Partners adjusts its rating for EchoIQ to Hold from Buy with its target price decreased to $1.50 from $2.00 following an FY26 result featuring an EBITDA loss of -$18.5m and an NPAT loss of -$18.6m.

Operating costs exceeded forecasts amid continued investment in US expansion, product development, and clinical validation across the cardiovascular market.

Subsequent to the period close, the business completed a $110m institutional placement to fund commercial readiness while awaiting FDA clearance for the EchoSolv HF product.

The valuation is lowered to reflect the dilutive capital issuance alongside higher short-term cost assumptions.

Shaw cites an expected total shareholder return below 10% alongside the pending regulatory outcome as justification for the downgrade.

FORECAST
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.20 cents.
Shaw and Partners forecasts a full year FY28 dividend of 0.00 cents and EPS of 1.60 cents.
Access Extra Coverage Research History >

EIQ STOCK CHART

FNArena News on EIQ

1
In Case You Missed It – BC Extra Upgrades & Downgrades – 04-09-26

Sep 04 2026 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Sep 01, 2026

Sep 01 2026 - Daily Market Reports
3
FNArena Corporate Results Monitor – 01-09-2026

Sep 01 2026 - Australia
4
Weekly Ratings, Targets, Forecast Changes – 03-07-26

Jul 06 2026 - Weekly Reports
5
Next Week At A Glance – 6-10 Jul 2026

Jul 03 2026 - Weekly Reports

Latest Medical Equipment & Devices News

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
3
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
4
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
5
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
6
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
7
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
8
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
9
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
10
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals